Guided by Data, Focused on Results

70% of rare disease patients lack the care they need. Everyone deserves access to life-changing treatment.

At Citrus, we leverage cutting-edge AI to unlock actionable insights from billions of medical records, transforming how we diagnose and treat various conditions. Our advanced models map out detailed patient journeys, analyzing disease progression, treatment efficacy, and long-term outcomes. By learning from the experiences of similar patients, we personalize treatment options to each individual’s unique needs. This approach allows us to accurately quantify key metrics like readmission rates, patient outcomes, and outpatient stays. 

In early 2024, Citrus partnered with a leading patient advocacy group focused on sickle cell disease (SCD) to evaluate and optimize treatment regimens. This collaboration resulted in notable improvements in patient care:  

• 30% reduction in disease severity progression: Our solutions identified the most effective treatments, reducing the frequency of pain crises by 20% and increasing hemoglobin levels from 6 - 11 g/dL to approximately 12 mg/dL. 

• Improved 30-day readmission rates: By directing patients to high-quality providers, we reduced the 30-day readmission rate for hospitalized patients from 40% to 15%.

• Fewer hospitalizations and emergency room visits: For early-diagnosis patients, our recommended transfusion therapies reduced hospitalizations from an average of 3.5 times per year to just 1, and decreased emergency room visits from 6 to 2.5 annually.

• Significant decrease in complications: The number of major complications fell from 4 to 1.4 per year, with the risk of infection dropping by 45%.

• Significant cost savings without compromising care: Bone marrow transplants can cost $250,000; however, Citrus-recommended providers deliver similar outcomes – such as readmission rates and outpatient stays – at just $150,000, offering significant savings without sacrificing care quality.